Significance of circulating tumor cells detection in tumor diagnosis and monitoring
-
Published:2023-12-06
Issue:1
Volume:23
Page:
-
ISSN:1471-2407
-
Container-title:BMC Cancer
-
language:en
-
Short-container-title:BMC Cancer
Author:
Liu Yuanrui,Zhao Rong,Xie Zaichun,Pang Zhiyu,Chen Shengjie,Xu Qian,Zhang Zhanfeng
Abstract
AbstractTo detect circulating tumor cells (CTCs) in the peripheral blood of patients with tumor, and to analyze the significance of CTC detection in tumor diagnosis and monitoring. In the present study, peripheral blood was collected from 125 patients with tumor, and CTCs were isolated and identified. Differences in CTC number and subtype detection were analyzed for different tumor diseases and stages. CTCs were detected in 122 of the 125 patients with tumor, with a positive rate of 97.6%. The number of CTCs increases in patients with vascular metastasis. The number of mesenchymal CTCs increases in patients with lymph node or vascular metastasis. The average ratio of epithelial CTCs in each positive sample decreases in the later stages of cancer compared with the earlier stages, while the average ratio of mesenchymal CTCs increases in the later stages of cancer compared with the earlier stages. The results showed that CTCs with mesenchymal phenotypes are closely related to lymph node or vascular metastasis. CTC detection can help with early diagnosis of tumor diseases. Continuous monitoring of changes in CTCs number and subtypes can assist clinical judgment of tumor disease development status and prognosis.
Funder
Guangdong Provincial Bureau of Traditional Chinese Medicine
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference34 articles.
1. Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The many facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. CELLS-BASEL 2021, 10(3). 2. Groenendijk A, Spreafico F, de Krijger RR, Drost J, Brok J, Perotti D, van Tinteren H, Venkatramani R, Godzinski J, Rube C et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. CANCERS 2021, 13(13). 3. Li Y, Ma Y, Wu Z, Xie R, Zeng F, Cai H, Lui S, Song B, Chen L, Wu M. Advanced Imaging techniques for differentiating pseudoprogression and Tumor Recurrence after Immunotherapy for Glioblastoma. FRONT IMMUNOL. 2021;12:790674. 4. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, et al. Fifteen-year outcomes after monitoring, Surgery, or Radiotherapy for Prostate Cancer. NEW ENGL J MED. 2023;388(17):1547–58. 5. Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating Tumor cells: biology and clinical significance. SIGNAL TRANSDUCT TAR. 2021;6(1):404.
|
|